129 related articles for article (PubMed ID: 30587628)
1. Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement.
Nieder C; Dalhaug A; Pawinski A
In Vivo; 2019; 33(1):229-232. PubMed ID: 30587628
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer.
Nieder C; Dalhaug A; Pawinski A
In Vivo; 2019; 33(2):465-468. PubMed ID: 30804126
[TBL] [Abstract][Full Text] [Related]
3. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma.
Partl R; Richtig E; Avian A; Berghold A; Kapp KS
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):662-6. PubMed ID: 22901382
[TBL] [Abstract][Full Text] [Related]
4. Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvement.
Nieder C; Marienhagen K; Dalhaug A; Aandahl G; Haukland E; Pawinski A
Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):447-52. PubMed ID: 24702741
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.
Lagerwaard FJ; Levendag PC; Nowak PJ; Eijkenboom WM; Hanssens PE; Schmitz PI
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):795-803. PubMed ID: 10098435
[TBL] [Abstract][Full Text] [Related]
6. Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels.
Nieder C; Marienhagen K; Dalhaug A; Norum J
ScientificWorldJournal; 2012; 2012():609323. PubMed ID: 22593701
[TBL] [Abstract][Full Text] [Related]
7. Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research.
Nieder C; Dalhaug A; Haukland E; Mannsåker B; Pawinski A
Tumour Biol; 2015 Aug; 36(8):6471-6. PubMed ID: 25801247
[TBL] [Abstract][Full Text] [Related]
8. Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement.
Nieder C; Dalhaug A; Mannsåker B
In Vivo; 2022; 36(2):801-805. PubMed ID: 35241535
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases.
Nieder C; Yobuta R; Mannsåker B
In Vivo; 2019; 33(1):173-176. PubMed ID: 30587619
[TBL] [Abstract][Full Text] [Related]
10. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
[TBL] [Abstract][Full Text] [Related]
11. Predicting prognosis of short survival time after palliative whole-brain radiotherapy.
Miyazawa K; Shikama N; Okazaki S; Koyama T; Takahashi T; Kato S
J Radiat Res; 2018 Jan; 59(1):43-49. PubMed ID: 29069502
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
[TBL] [Abstract][Full Text] [Related]
13. KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.
Partl R; Fastner G; Kaiser J; Kronhuber E; Cetin-Strohmer K; Steffal C; Böhmer-Breitfelder B; Mayer J; Avian A; Berghold A
Support Care Cancer; 2016 Feb; 24(2):523-528. PubMed ID: 26105515
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum lactate dehydrogenase level predicts progression and prognosis in patients with glioma.
Chen XY; Chen JY; Chen Y; Chen JF; Lin N; Ding CY; Kang DZ; Wang DL; Fang WH
Clin Neurol Neurosurg; 2021 Oct; 209():106912. PubMed ID: 34509141
[TBL] [Abstract][Full Text] [Related]
16. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.
Lee DS; Park KR; Kim SJ; Chung MJ; Lee YH; Chang JH; Kang JH; Hong SH; Kim MS; Kim YS
Tumour Biol; 2016 Jan; 37(1):619-25. PubMed ID: 26240025
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.
Inoue T; Katoh N; Aoyama H; Onimaru R; Taguchi H; Onodera S; Yamaguchi S; Shirato H
Jpn J Clin Oncol; 2010 Aug; 40(8):788-94. PubMed ID: 20406944
[TBL] [Abstract][Full Text] [Related]
18. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
19. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
[TBL] [Abstract][Full Text] [Related]
20. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
